Bio-Rad Laboratories, Inc. (BIO) achieves modest revenue growth and robust free cash flow growth
Bio-Rad Laboratories (BIO) reported modest revenue growth of 2.1% but demonstrated strong free cash flow growth of 30.7%. Despite this, the company's valuation appears stretched with a Price-to-Earnings (P/E) ratio of 55.4 and an Enterprise Value to Sales (EV/Sales) of 4.7. Investors should consider the potential for growth to decelerate and how that might impact future returns, especially given the current valuation.
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain
Bio-Rad's revenue growth recovery is facing uncertainty, pushed back by its 2026 guidance. The company, a leader in life sciences research and clinical diagnostics, relies on a "razor-and-blade" model with consumables accounting for about 70% of sales. Despite a soft market, previous reports indicated the company was on track to meet full-year targets.
BIO-RAD LABORATORIES, INC. SEC 10-K Report
Bio-Rad Laboratories, Inc. has released its annual Form 10-K report for the fiscal year ended December 31, 2025, detailing financial performance, business operations, and strategic initiatives. The company reported net sales of $2,583.2 million, a significant increase in net income to $759.9 million, and continued challenges in the biopharma market. Strategic initiatives include the acquisition of Stilla Technologies and maintaining a strong liquidity position, while significant risks include market competition, supply chain disruptions, and global economic conditions.
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q4 Revenue $693.2M, vs. FactSet Est of $688.8M
Bio-Rad Laboratories, Inc. (BIO) reported its Q4 revenue at $693.2 million, surpassing the FactSet estimate of $688.8 million. This earnings flash highlights the company's financial performance, specifically its revenue outperforming analyst expectations for the fourth quarter.
Mawer Investment Management Ltd. Reduces Holdings in Bio-Rad Laboratories, Inc. $BIO
Mawer Investment Management Ltd. significantly reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.9% in Q3, selling 23,640 shares. Despite this reduction, other institutional investors, such as First Eagle Investment Management LLC, increased their holdings, and institutional investors collectively own 65.24% of the company's stock. Analyst ratings for Bio-Rad are mixed, with a consensus "Hold" rating and an average price target of $358.50, although some analysts have upgraded their ratings or price targets.
Trading Systems Reacting to (BIO) Volatility
This article analyzes Bio-rad Laboratories Inc. Class A (NYSE: BIO), noting weak near and mid-term sentiment despite a long-term positive outlook. It highlights a mid-channel oscillation pattern and presents an exceptional 42.2:1 risk-reward setup targeting a 12.2% gain. The piece outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors.
What Bio-Rad Laboratories (BIO)'s AI-Driven Protein Assay Upgrades Mean For Shareholders
Bio-Rad Laboratories has enhanced its protein assay portfolio with more sensitive kits and integrated AI, IoT, and blockchain to improve accuracy and efficiency, broadening their application in research and diagnostics. While these upgrades align with Bio-Rad's strategy as a core tools provider, they are not yet considered a major catalyst for the company's investment narrative, which currently focuses on margin improvement, management execution, and share buybacks amidst weak stock performance and modest revenue growth. The article also notes that Bio-Rad’s shares might still be overvalued, despite recent corrections.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Hold" from Analysts
Bio-Rad Laboratories (NYSE:BIO) has received an average "Hold" rating from six analysts, with an average 12-month target price of $358.50. The company's stock currently trades around $295.92 and has a market capitalization of approximately $7.98 billion. Recent financial results showed an EPS of $2.26, missing estimates, and an EVP recently sold 700 shares.
Is Bio-Rad Laboratories (BIO) Starting To Look Attractive After Prolonged Share Price Weakness?
Bio-Rad Laboratories (BIO) has experienced significant share price weakness over recent years but is currently scoring as undervalued based on Simply Wall St's checklist-based valuation framework. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 22.2%, and its Price/Sales ratio also indicates a modest discount compared to its "Fair Ratio." The article encourages investors to use "Narratives" on Simply Wall St's platform to personalize their valuation based on individual assumptions.
SG Americas Securities LLC Buys 5,600 Shares of Bio-Rad Laboratories, Inc. $BIO
SG Americas Securities LLC significantly increased its stake in Bio-Rad Laboratories (NYSE:BIO) by 688% in the third quarter, acquiring an additional 5,600 shares, bringing its total to 6,414 shares valued at $1.798 million. Despite this institutional buying, an EVP insider sold 700 shares, reducing his holding by nearly 58%. Bio-Rad Laboratories reported Q3 EPS of $2.26, slightly missing consensus estimates, and currently holds a "Hold" consensus rating from analysts with a target price of $358.50.
(BIO) and the Role of Price-Sensitive Allocations
This article provides a detailed analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting a strong near and mid-term sentiment and an exceptional risk-reward short setup. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and AI-generated signals for support and resistance levels. The analysis suggests a potential 13.6% downside versus a 0.3% risk based on current signals.
Responsive Playbooks and the BIO Inflection
This article provides an AI-driven analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting a neutral near-term sentiment and a mid-channel oscillation pattern. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis and an exceptional risk-reward setup targeting a 16.4% gain.
Liquidity Mapping Around (BIO) Price Events
The article provides a detailed liquidity mapping analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It outlines institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for potential price movements. The analysis identifies key support and resistance levels and suggests a highly favorable risk-reward setup.
Avoiding Lag: Real-Time Signals in (BIO) Movement
Bio-rad Laboratories Inc. Class A (NYSE: BIO) is showing strong near-term sentiment that could challenge persistent mid and long-term weakness. The article highlights an exceptional 56.8:1 risk-reward short setup targeting a 16.3% downside versus a 0.3% risk. AI models have generated distinct trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Bio-Rad Laboratories (BIO): Assessing Valuation Following Q3 Loss and Share Buyback Completion
Bio-Rad Laboratories (BIO) reported a Q3 net loss and completed a share buyback, leading to an 11.9% share price rebound recently despite long-term underperformance. The company is considered 5.1% undervalued with a fair value of $324, driven by expanded molecular diagnostics platforms and strategic acquisitions. However, this optimism is tempered by persistent instrument demand weakness and margin pressures.
BIO-RAD LABORATORIES Earnings Results: $BIO Reports Quarterly Earnings
BIO-RAD LABORATORIES ($BIO) reported its quarterly earnings on October 29th, with earnings per share of $2.26, surpassing the estimated $1.95. However, the company missed revenue estimates, reporting $653 million against an expectation of $657.81 million. The article also provides details on hedge fund activity, government contracts received by $BIO, and recent analyst ratings and price targets.
Bio-Rad Laboratories (BIO): Evaluating Valuation After Major Oncology Diagnostics Partnership Expansion with Biodesix
Bio-Rad Laboratories and Biodesix are expanding their partnership to develop new in vitro diagnostic assays for oncology, leveraging Bio-Rad's Droplet Digital PCR technology. While the stock has seen a recent surge, its five-year returns remain negative, prompting questions about its current valuation. Analysts present differing fair value assessments, with some suggesting overvaluation while a Discounted Cash Flow model indicates significant undervaluation.
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
Biodesix has announced an expanded partnership with Bio-Rad Laboratories to develop and clinically validate in vitro diagnostic (IVD) assays using Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology. The initial focus is on the ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer, which will help detect ESR1 mutations from ctDNA samples. This collaboration aims to provide sensitive biomarker detection for cancer treatment monitoring and support targeted therapeutic development.
Biodesix Expands Partnership with Bio-Rad for Development of Advanced Cancer Diagnostics Using ddPCR Technology
Biodesix has expanded its partnership with Bio-Rad to develop and validate in vitro diagnostic assays for sensitive genomic marker detection in oncology, utilizing Bio-Rad's Droplet Digital™ PCR technology. The initial focus will be on the ddPLEX ESR1 Mutation Detection Assay, crucial for advanced breast cancer treatment. Once validated, Biodesix will offer the assay through its accredited laboratory and seek CMS reimbursement, expanding its personalized medicine offerings.
Earnings call transcript: Bio-Rad Labs Q2 2025 shows steady growth - Investing.com India
This article from Investing.com India is an earnings call transcript for Bio-Rad Labs' Q2 2025, which indicates steady growth for the company. However, the full article content is replaced by an application error message, preventing the display of the actual transcript details.
Earnings call transcript: Bio-Rad Labs Q2 2025 shows steady growth - Investing.com Canada
This article states that a client-side exception has occurred while loading the Investing.com Canada website, preventing the display of the Bio-Rad Labs Q2 2025 earnings call transcript. As a result, no information regarding the earnings call or Bio-Rad Labs' performance is available within the provided content. The current content is an error message.
Sivik Global Healthcare LLC Makes New Investment in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Sivik Global Healthcare LLC has made a new investment in Bio-Rad Laboratories, acquiring 18,000 shares valued at approximately $4.34 million, making it their 25th largest portfolio position. Bio-Rad Laboratories reported strong Q2 earnings with $2.61 EPS, surpassing analyst expectations, and revenue increased by 2.1% year-over-year. Institutional investors and hedge funds own 65.24% of the stock, indicating significant institutional interest in the medical research company.
Bio-Rad Laboratories (NYSE:BIO.B) Stock Price Up 15.3% - Here's What Happened
Bio-Rad Laboratories (NYSE:BIO.B) stock surged 15.3% to $284.88 during Friday's mid-day trading with a significant increase in trading volume. The company reported $2.61 EPS for the last quarter and revenue of $651.60 million, operating in life science research and clinical diagnostics. This report highlights company performance and financial metrics.
Investors in Bio-Rad Laboratories (NYSE:BIO) have unfortunately lost 47% over the last five years
Bio-Rad Laboratories (NYSE:BIO) shareholders have seen a 47% loss over the last five years, despite a recent 12% quarterly gain. This underperformance contrasts with the company becoming profitable within the last five years, though its revenue has slightly decreased annually. Investors are cautioned to look beyond short-term performance and consider the company's full financial position, noting two warning signs in its investment analysis.
When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Bio-Rad Laboratories (NYSE:BIO) has seen significant price increases recently but is trading around industry price multiples. The company is forecast to have highly negative earnings growth, which increases the risk for investors and suggests it may not be an advantageous time to buy. Shareholders may consider de-risking their portfolios given the uncertain future outlook.
10 Undervalued Stocks That Crushed Q2 Earnings
This article identifies 10 undervalued US-listed stocks that significantly exceeded Q2 earnings and revenue expectations. Companies like Pfizer, Bristol-Myers Squibb, and DraftKings are highlighted, with Morningstar analysts providing commentary on their performance and continued undervaluation. The selection process involved screening for strong beats, economic moats, and high Morningstar Ratings.
Earnings call transcript: Bio-Rad Labs beats Q2 2025 forecasts, shares dip
Bio-Rad Laboratories reported strong Q2 2025 results, with EPS of $2.61 significantly surpassing the forecast of $1.73 and revenue reaching $651.6 million, exceeding expectations. Despite these positive financial outcomes, the company's stock experienced a 3.25% dip in aftermarket trading, reflecting broader market trends and ongoing challenges in the Chinese market and academic research funding. Bio-Rad also raised its full-year currency-neutral revenue guidance to flat to 1% growth and updated its operating margin projection to 12-13%, partly due to reduced tariff headwinds.
DNA Diagnostics Market Size, Industry Advancements, Opportunities And Forecast 2033
The global DNA diagnostics market is projected to grow from $11.54 billion in 2025 to $23.24 billion by 2033, exhibiting a CAGR of 9.15%. This growth is driven by the increasing adoption of personalized medicine, rising prevalence of genetic and chronic diseases, and advancements in point-of-care diagnostics. North America currently dominates the market, while Asia-Pacific is identified as the fastest-growing region.
Bio-Rad Earnings: Revenue Declines Driven by Weak Academic Research Market; Guidance Lowered
Bio-Rad reported a 1.5% year-on-year revenue decline at constant currency, primarily due to weak equipment sales in life sciences, stemming from low demand in the academic research market. Management subsequently lowered its guidance, citing tariffs and continued softness in both academia and biotech markets. This downward revision comes despite earlier hopes for improving demand in life sciences.
Bio-Rad's Steady Business and Stake in Sartorius Driving Long-Term Value
This article discusses Bio-Rad Laboratories' steady business model, which is driven by its strong position in life sciences research and clinical diagnostics markets and its significant stake in Sartorius. The company operates on a "razor-and-blade" model, with consumables accounting for a large portion of its sales. Analyst notes indicate that Bio-Rad is on track to meet full-year targets despite soft market demand, with some signs of improving demand in life sciences.
Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%
Institutional investors own 60% of Bio-Rad Laboratories, Inc. (NYSE:BIO), indicating significant influence over the company's stock price. The top 10 shareholders collectively own 51%, while company insiders hold a 14% stake. This breakdown suggests a balance of large institutional impact and insider alignment, with the general public owning 13% and private companies owning another 13%.
Bio-Rad Laboratories Inc. Class A (BIO) reports earnings
Bio-Rad Laboratories Inc. Class A (BIO) reported a decrease in net sales to $2.57 billion for the fiscal year ended December 31, 2024, primarily due to lower sales in its Life Science segment. The company also reported a net loss of $1.84 billion, largely impacted by losses from changes in the fair market value of equity securities. Bio-Rad announced a restructuring plan to improve operating performance, expected to be completed by the end of fiscal year 2025.
Earnings call transcript: Bio-Rad Q4 2024 results miss forecasts
Bio-Rad Laboratories Inc (NYSE: BIO) reported Q4 2024 earnings, missing revenue forecasts with $668 million against an expected $681.29 million, but slightly beating EPS estimates at $2.90 versus $2.86. The company's stock declined following the announcement, reflecting investor concerns over the revenue miss and market conditions in its Life Science Group, which saw a 12.8% decline. Bio-Rad anticipates a modest recovery and 1.5% to 3.5% currency-neutral revenue growth for 2025, driven by strategic acquisitions like STILA Technologies and ongoing product innovation.
Improve mAb Purification Process Efficiency With Mixed-Mode Resins
This application note evaluates the efficacy of different mAb purification workflows, comparing a conventional three-step method with two streamlined two-step approaches. The two-step workflows demonstrated higher yields of the target mAb and superior removal of leached Protein A while maintaining comparable purity, host cell protein, and DNA removal. The findings suggest that simplified purification methods can significantly improve efficiency without compromising the quality of the purified mAb.
Bio-Rad Receives NF Validation for iQ-Check Listeria spp. and iQ-Check Listeria monocytogenes Shortened Enrichment Protocol
Bio-Rad Laboratories, Inc. has announced that its iQ-Check Listeria spp. and iQ-Check Listeria monocytogenes Kits have received NF Validation for a shortened enrichment protocol. This new protocol, utilizing LSB II broth, significantly reduces the time to results to less than 24 hours, enhancing the efficiency of Listeria detection in food products and environmental samples. The validation underscores the protocol's effectiveness and reliability, critical for ensuring food safety.
Bio-Rad Laboratories drives innovation with products and advancements in 2024
Bio-Rad Laboratories has made significant advancements in 2024, launching numerous cutting-edge products and achieving key regulatory milestones, particularly in oncology and molecular diagnostics. The company's innovations include IVDR Class C certification for its QXDx BCR-ABL %IS Kit, new gene therapy quantification solutions, expanded tools for flow cytometry, and advancements in single-cell and digital PCR technology. Bio-Rad also achieved regulatory approval for its dd-Check STEC Solution for food safety and published a study on its SpyLock technology for antibody development.
Bio-Rad Laboratories: This Undervalued Stock Offers Investors a Rare Combination
Bio-Rad Laboratories, a small-cap company with a wide economic moat, is highlighted as an undervalued stock offering a rare combination for investors. The company specializes in clinical diagnostics and life sciences, maintaining leadership in niche markets and benefiting from high switching costs and a significant stake in Sartorius. Morningstar estimates a fair value of $430 per share for Bio-Rad, noting its leadership positions, recurring revenue model, and potential for margin expansion, despite competitive risks and historical operational inefficiencies.
Bio-Rad Launches System for Benchtop Gel and Western Blot Imaging
Bio-Rad Laboratories has launched the ChemiDoc™ Go Imaging System, a new benchtop device for rapid, reliable, and highly sensitive gel and western blot imaging. This system utilizes CMOS digital imaging and supports advanced chemiluminescence and fluorescence detection with StarBright™ Dyes, offering versatility for various applications. It also features all-LED illumination and compatibility with Bio-Rad's cloud-based platform, BR.io, simplifying workflows and enhancing data accessibility.
Wall Street’s 10 favorite stocks for 2024
This article identifies Wall Street's top 10 stock picks for 2024 based on analyst ratings and implied upside potential. The list, derived from S&P 500 companies with at least 75% "buy" ratings, includes stocks like Nvidia, First Solar, and Halliburton, highlighting the optimistic outlook following investor confidence in the Federal Reserve's interest rate decisions.
Qiagen’s Thierry Bernard named chair of the AdvaMedDx board
Thierry Bernard, CEO of Qiagen, has been appointed as the new chair of the AdvaMedDx board of directors, succeeding Norman Schwartz of Bio-Rad Laboratories. AdvaMedDx is the diagnostics division of the trade association AdvaMed, representing over 75 in-vitro diagnostic manufacturers. Bernard, who joined Qiagen in 2015 and became CEO in 2019, expressed his commitment to ensuring patient and provider access to reliable diagnostics.
Malaysia, Singapore and Indonesia In-Vitro Diagnostics (IVD) Market Report 2022 with Market Share of Leading Players - Roche, Abbott, Siemens Healthineers, Beckman Coulter, bioMerieux, Bio-Rad, Sysmex
This report from ResearchAndMarkets.com analyzes the In-Vitro Diagnostics (IVD) market in Malaysia, Singapore, and Indonesia, highlighting the significant growth opportunities in Southeast Asia for IVD companies. It covers market segments, key companies, and country-specific healthcare landscapes, including the impact of COVID-19 testing trends. The report also details market shares of leading IVD companies such as Roche, Abbott, and Siemens Healthineers.
Should You Buy Bio-Rad Laboratories Stock After Its 50% Fall This Year?
Bio-Rad Laboratories stock (NYSE: BIO) experienced a significant 48% fall this year, underperforming the S&P500 index. Despite this, its long-term returns since late 2017 have outpaced the S&P 500, suggesting it may now be undervalued. The article discusses factors influencing its stock performance, including revenue growth, P/S ratio changes, and a potential merger with Qiagen, concluding that the current dip might offer a good investment opportunity.
East Bay life sciences company reportedly in talks with Qiagen in $10 billion deal
Bio-Rad Laboratories, an East Bay life sciences company, is reportedly in discussions with Qiagen for a potential $10 billion deal. This news comes as Bio-Rad, founded in Berkeley in the 1950s, has grown to nearly 8,000 employees globally. The article also references related news about other biotech companies, suggesting a dynamic environment in the life sciences sector.
Bio-Rad Laboratories, Inc. (BIO) Company Information
This report provides company information for Bio-Rad Laboratories, Inc. (NYSE:BIO), detailing its key information such as ticker, exchange, founding year, industry, sector, market cap, and employee numbers. It also covers the company's listings on various exchanges, data sources used for analysis, and a list of analysts who cover the company.
Bio-Rad Trims Claims From Infringement Suit by Danaher’s Cytiva
A federal judge ruled that Bio-Rad Laboratories Inc.'s protein purification system does not infringe on six of eight patent claims asserted by Danaher Corp.'s Cytiva Sweden. The ruling, issued in the U.S. District Court for the District of Delaware, granted Bio-Rad's motion for summary judgment regarding its Next Generation Chromatography (NGC) system. The judge agreed with Bio-Rad that Cytiva failed to provide sufficient evidence of direct infringement for these claims.
Point of Care Diagnostics Market Size to Hit USD 93.21 Bn by 2030
The global point of care diagnostics market is projected to reach USD 93.21 billion by 2030, growing at an 11.1% CAGR from 2021 to 2030, driven by rising chronic diseases, technological advancements, and the aging population. North America currently leads the market, while Asia-Pacific is set to be the fastest-growing region. Challenges include stringent regulatory frameworks and inadequate adoption due to lack of training for clinical professionals.
Bio-Rad introduces CFX Opus Dx real-time PCR detection systems for IVD use
Bio-Rad Laboratories has launched the CFX Opus 96 Dx System and the CFX Opus 384 Dx System, which are real-time PCR detection systems for IVD use. These systems are listed with the U.S. FDA and meet CE-IVD requirements for Europe, as well as being registered in Singapore and Canada. They offer accurate and precise quantification, improving assay development and workflow efficiencies for diagnostic testing and research.
‘Shining example’: Sale of Fort Worth biotech firm highlights strength of innovation hub
The sale of Fort Worth biotech startup Exact Diagnostics for $60 million to Bio-Rad highlights the city's growing status as a research and innovation hub. This acquisition, coupled with Exact Diagnostics' plan to relocate to the Near Southside, further strengthens the area's reputation as a center for biotech, building on previous high-value acquisitions of other local startups. The success is attributed in part to local incubators and the University of North Texas Health Science Center.
10x Genomics IPO Starts Out Strong, as Bio-Rad Files Third Patent Lawsuit
10x Genomics successfully launched its IPO, raising an estimated $357.5 million, with its share price climbing significantly on the first day of trading. This strong IPO launch occurred despite Bio-Rad filing its third patent infringement lawsuit against 10x Genomics, this time targeting its Next GEM products. The ongoing legal battles with Bio-Rad, including past damage awards and injunctions, pose a significant risk to 10x Genomics' business.
Investigators Develop Blood Tests to Monitor Melanoma
NYU Langone Health researchers, including Dr. David Polsky and Dr. Iman Osman, are developing "liquid biopsies" in collaboration with Bio-Rad Laboratories to monitor melanoma by detecting tumor DNA in the bloodstream. These blood tests aim to overcome limitations of traditional biopsies, providing a less invasive, faster, and more cost-effective way to identify gene mutations and track cancer progression. The technology holds significant promise for personalized cancer management, allowing earlier detection of treatment resistance and guiding therapy adjustments for melanoma and other cancers like lung cancer.
